Please wait a minute...
J Zhejiang Univ (Med Sci)  2020, Vol. 49 Issue (6): 772-778    DOI: 10.3785/j.issn.1008-9292.2020.12.13
    
Tissue factors and venous thromboembolism in cancer patients
ZHU Huiqi(),YING Kejing*()
Department of Respiratory Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, National Regional Medical Center for Respiratory Diseases, Hangzhou 310016, China
Download: HTML( 18 )   PDF(1030KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

Malignant tumor is one of the important acquired risk factors of venous thromboembolism (VTE). As the transmembrane receptor of coagulation factor Ⅶ and activated coagulation factor Ⅶa in vivo, tissue factor is the main initiator of exogenous coagulation. Tissue factor positive particles expressed and released by tumor cells enter the circulation and mediate thrombosis in patients with surgical treatment and distant tumor metastasis; the enhanced procoagulant activity of tissue factor after chemotherapy makes many cancer patients more likely to develop thromboembolic disease. Tissue factors can also be used to predict the risk of VTE in patients with pancreatic cancer, colorectal cancer and ovarian cancer.This article summarizes the role of tissue factor in VTE of cancer patients at different treatment stages, and further clarifies the relationship between tissue factor and the risk of VTE in cancer patients.



Key wordsVenous thromboembolism      Tissue factors      Tumor therapy      Neoplasm metastasis      Prediction      Review     
Received: 10 July 2020      Published: 14 January 2021
CLC:  R364.1+5  
  R730.2  
Corresponding Authors: YING Kejing     E-mail: 21818343@zju.edu.cn;3197061@zju.edu.cn
Cite this article:

ZHU Huiqi,YING Kejing. Tissue factors and venous thromboembolism in cancer patients. J Zhejiang Univ (Med Sci), 2020, 49(6): 772-778.

URL:

http://www.zjujournals.com/med/10.3785/j.issn.1008-9292.2020.12.13     OR     http://www.zjujournals.com/med/Y2020/V49/I6/772


组织因子与肿瘤患者静脉血栓栓塞

恶性肿瘤是静脉血栓栓塞(VTE)的重要获得性危险因素之一。组织因子作为体内凝血因子Ⅶ和活化形式的凝血因子Ⅶa的跨膜受体,是机体外源性凝血过程的主要起始物。肿瘤细胞表达释放的组织因子阳性微粒进入循环参与介导手术治疗和肿瘤远处转移患者的血栓形成;化疗后组织因子促凝活性增强导致很多肿瘤患者接受化疗后更容易发生血栓栓塞性疾病。在胰腺癌、结直肠癌和卵巢癌等肿瘤中,组织因子还可以用于预测患者VTE风险。本文总结了近年来组织因子在不同治疗阶段的肿瘤患者VTE中的作用,进一步明确组织因子与肿瘤患者VTE风险之间的关系。


关键词: 静脉血栓栓塞,  组织因子,  肿瘤治疗,  肿瘤转移,  风险预测,  综述 
[1]   PABINGER I , THALER J , AY C . Biomarkers for prediction of venous thromboembolism in cancer[J]. Blood, 2013, 122 (12): 2011- 2018
doi: 10.1182/blood-2013-04-460147
[2]   TIMP J F , BRAEKKAN S K , VERSTEEG H H et al. Epidemiology of cancer-associated venous thrombosis[J]. Blood, 2013, 122 (10): 1712- 1723
doi: 10.1182/blood-2013-04-460121
[3]   FALANGA A , PANOVA-NOEVA M , RUSSO L . Procoagulant mechanisms in tumour cells[J]. Best Pract Res Clin Haematol, 2009, 22 (1): 49- 60
doi: 10.1016/j.beha.2008.12.009
[4]   FALANGA A , MARCHETTI M , VIGNOLI A . Coagulation and cancer: biological and clinical aspects[J]. J Thromb Haemost, 2013, 11 (2): 223- 233
doi: 10.1111/jth.12075
[5]   EDWARDS R L , MORGAN D L , RICKLES F R . Animal tumor procoagulants: registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society of Thrombosis and Haemostasis[J]. Thromb Haemost, 1990, 63 (1): 133- 138
doi: 10.1055/s-0038-1645699
[6]   MACKMAN N , MORRISSEY J H , FOWLER B et al. Complete sequence of the human tissue factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade[J]. Biochemistry, 1989, 28 (4): 1755- 1762
doi: 10.1021/bi00430a050
[7]   ZAHRA S , ANDERSON J A , STIRLING D et al. Microparticles, malignancy and thrombosis[J]. Br J Haematol, 2011, 152 (6): 688- 700
doi: 10.1111/j.1365-2141.2010.08452.x
[8]   KOMIYAMA Y , PEDERSEN A H , KISIEL W . Proteolytic activation of human factors Ⅸ and Ⅹ by recombinant human factor Ⅶa: effects of calcium, phospholipids, and tissue factor[J]. Biochemistry, 1990, 29 (40): 9418- 9425
doi: 10.1021/bi00492a016
[9]   ZWICKER J I , LIEBMAN H A , NEUBERG D et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy[J]. Clin Cancer Res, 2009, 15 (22): 6830- 6840
doi: 10.1158/1078-0432.CCR-09-0371
[10]   DRAKE T A , MORRISSEY J H , EDGINGTON T S . Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis[J]. AM J PATHOL, 1989, 134 (5): 1087- 1097
[11]   FLECK R A , RAO L V , RAPAPORT S I et al. Localization of human tissue factor antigen by immunostaining with monospecific, polyclonal anti-human tissue factor antibody[J]. Thromb Res, 1990, 59 (2): 421- 437
doi: 10.1016/0049-3848(90)90148-6
[12]   OTT I . Soluble tissue factor emerges from inflammation[J]. Circ Res, 2005, 96 (12): 1217- 1218
doi: 10.1161/01.RES.0000172745.09928.87
[13]   FONSECA R , CESARMAN-MAUS G , BRAGGIO E . Personalizing the use of circulating microparticle-associated tissue factor as a biomarker for recurrent thrombosis in patients with cancer[J]. J Clin Oncol, 2017, 35 (19): 2217- 2218
doi: 10.1200/JCO.2017.72.5341
[14]   MANLY D A , BOLES J , MACKMAN N . Role of tissue factor in venous thrombosis[J]. Annu Rev Physiol, 2011, 73:515- 525
doi: 10.1146/annurev-physiol-042210-121137
[15]   DVORAK H F , NAGY J A , DVORAK J T et al. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules[J]. Am J Pathol, 1988, 133 (1): 95- 109
[16]   AUWERDA J J , YUANA Y , OSANTO S et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma[J]. Thromb Haemost, 2011, 105 (1): 14- 20
doi: 10.1160/TH10-03-0187
[17]   WANG J G , GEDDINGS J E , ALEMAN M M et al. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer[J]. Blood, 2012, 119 (23): 5543- 5552
doi: 10.1182/blood-2012-01-402156
[18]   EDGINGTON T S , MACKMAN N , BRAND K et al. The structural biology of expression and function of tissue factor[J]. Thromb Haemost, 1991, 66 (1): 67- 79
doi: 10.1055/s-0038-1646375
[19]   PEPPELENBOSCH M P , VERSTEEG H H . Cell biology of tissue factor, an unusual member of the cytokine receptor family[J]. Trends Cardiovasc Med, 2001, 11 (8): 335- 339
doi: 10.1016/s1050-1738(01)00137-2
[20]   GORDON S G , MIELICKI W P . Cancer procoagulant: a factor X activator, tumor marker and growth factor from malignant tissue[J]. Blood Coagul Fibrinolysis, 1997, 8 (2): 73- 86
doi: 10.1097/00001721-199703000-00001
[21]   WOOD K E . Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism[J]. Chest, 2002, 121 (3): 877- 905
doi: 10.1378/chest.121.3.877
[22]   BATTISTINI B . Modulation and roles of the endothelins in the pathophysiology of pulmonary embolism[J]. Can J Physiol Pharmacol, 2003, 81 (6): 555- 569
doi: 10.1139/y03-017
[23]   LAWSON C A , YAN S D , YAN S F et al. Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation[J]. J Clin Invest, 1997, 99 (7): 1729- 1738
doi: 10.1172/JCI119337
[24]   WOEI-A-JIN F J , TESSELAAR M E , GARCIA RODRIGUEZ P et al. Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis?[J]. Br J Cancer, 2016, 115 (3): 332- 338
doi: 10.1038/bjc.2016.170
[25]   AHAMED J , VERSTEEG H H , KERVER M et al. Disulfide isomerization switches tissue factor from coagulation to cell signaling[J]. Proc Natl Acad Sci U S A, 2006, 103 (38): 13932- 13937
doi: 10.1073/pnas.0606411103
[26]   PRANDONI P . Antithrombotic strategies in patients with cancer[J]. Thromb Haemost, 1997, 78 (1): 141- 144
doi: 10.1055/s-0038-1657517
[27]   ERNOFSSON M , THELIN S , SIEGBAHN A . Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study[J]. J Thoracic Cardiovas Surg, 1997, 113 (3): 576- 584
doi: 10.1016/S0022-5223(97)70373-8
[28]   CHUNG J , TABUCHI N , KOYAMA T . The increase in tissue factor-bearing leukocytes after off-pump coronary artery bypass surgery[J]. Thromb Haemost, 2008, 100 (5): 952- 954
doi: 10.1160/TH08-06-0349
[29]   DE MARTINO R R , GOODNEY P P , SPANGLER E L et al. Variation in thromboembolic complications among patients undergoing commonly performed cancer operations[J]. J Vasc Surg, 2012, 55 (4): 1035- 1040.e4
doi: 10.1016/j.jvs.2011.10.129
[30]   ALBRECHT S , MVLLER S , SIEGERT G et al. Plasma concentration of tissue factor and factor Ⅶ in patients after abdominal surgery[J]. Thromb Res, 1995, 77 (6): 557- 562
doi: 10.1016/0049-3848(95)00030-5
[31]   MERKOW R P , BILIMORIA K Y , MCCARTER M D et al. Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis[J]. Ann Surg, 2011, 254 (1): 131- 137
doi: 10.1097/SLA.0b013e31821b98da
[32]   HEIT J A , SILVERSTEIN M D , MOHR D N et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study[J]. Arch Intern Med, 2000, 160 (6): 809- 815
doi: 10.1001/archinte.160.6.809
[33]   GRACE R F , DAHLBERG S E , NEUBERG D et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols[J]. Br J Haematol, 2011, 152 (4): 452- 459
doi: 10.1111/j.1365-2141.2010.08524.x
[34]   AMIR E , SERUGA B , NIRAULA S et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis[J]. J Natl Cancer Inst, 2011, 103 (17): 1299- 1309
doi: 10.1093/jnci/djr242
[35]   OPPELT P , BETBADAL A , NAYAK L . Approach to chemotherapy-associated thrombosis[J]. Vasc Med, 2015, 20 (2): 153- 161
doi: 10.1177/1358863X14568705
[36]   SENG S , LIU Z , CHIU S K et al. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis[J]. J Clin Oncol, 2012, 30 (35): 4416- 4426
doi: 10.1200/JCO.2012.42.4358
[37]   FALANGA A , MARCHETTI M . Anticancer treatment and thrombosis[J]. Thromb Res, 2012, 129 (3): 353- 359
doi: 10.1016/j.thromres.2011.10.025
[38]   BACH R R , MOLDOW C F . Mechanism of tissue factor activation on HL-60 cells[J]. Blood, 1997, 89 (9): 3270- 3276
doi: 10.1182/blood.V89.9.3270
[39]   LYSOV Z , SWYSTUN L L , KURUVILLA S et al. Lung cancer chemotherapy agents increase procoagulant activity via protein disulfide isomerase-dependent tissue factor decryption[J]. Blood Coagul Fibrinolysis, 2015, 26 (1): 36- 45
doi: 10.1097/MBC.0000000000000145
[40]   JACOBSEN C , OECHSLE K , HAUSCHILD J et al. Regulation of tissue factor in NT2 germ cell tumor cells by cisplatin chemotherapy[J]. Thromb Res, 2015, 136 (3): 673- 681
doi: 10.1016/j.thromres.2015.07.002
[41]   BILLROTH T . General surgical pathology and therapy. Guidance for students and physicians. Lecture[J]. Khirurgiia (Mosk), 1991, (10): 136- 143
[42]   ELIZONDO P , FOGELSON A L . A mathematical model of venous thrombosis initiation[J]. Biophys J, 2016, 111 (12): 2722- 2734
doi: 10.1016/j.bpj.2016.10.030
[43]   FAILLE D , BOURRIENNE M C , DE RAUCOURT E et al. Biomarkers for the risk of thrombosis in pancreatic adenocarcinoma are related to cancer process[J]. Oncotarget, 2018, 9 (41): 26453- 26465
doi: 10.18632/oncotarget.25458
[44]   RONDON A , KROONE C , KAPTEIJN M Y et al. Role of tissue factor in tumor progression and cancer-associated thrombosis[J]. Semin Thromb Hemost, 2019, 45 (4): 396- 412
doi: 10.1055/s-0039-1687895
[45]   TSENG J C , CHANG L C , JIANG B Y et al. Elevated circulating levels of tissue factor-positive microvesicles are associated with distant metastasis in lung cancer[J]. J Cancer Res Clin Oncol, 2014, 140 (1): 61- 67
doi: 10.1007/s00432-013-1544-8
[46]   KHORANA A A , FRANCIS C W , MENZIES K E et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer[J]. J Thromb Haemost, 2008, 6 (11): 1983- 1985
doi: 10.1111/j.1538-7836.2008.03156.x
[47]   TESSELAAR M E , ROMIJN F P , VAN DER LINDEN I K et al. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis[J]. J Thromb Haemost, 2009, 7 (8): 1421- 1423
doi: 10.1111/j.1538-7836.2009.03504.x
[48]   KHORANA A A , AHRENDT S A , RYAN C K et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer[J]. Clin Cancer Res, 2007, 13 (10): 2870- 2875
doi: 10.1158/1078-0432.CCR-06-2351
[49]   HRON G , KOLLARS M , WEBER H et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer[J]. Thromb Haemost, 2007, 97 (1): 119- 123
doi: 10.1160/TH06-03-0141
[50]   AY C , VORMITTAG R , DUNKLER D et al. D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study[J]. J Clin Oncol, 2009, 27 (25): 4124- 4129
doi: 10.1200/JCO.2008.21.7752
[51]   UNO K , HOMMA S , SATOH T et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer[J]. Br J Cancer, 2007, 96 (2): 290- 295
doi: 10.1038/sj.bjc.6603552
[52]   GEZELIUS E , FLOU KRISTENSEN A , BENDAHL P O et al. Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: a sub-study of RASTEN - a randomized trial with low molecular weight heparin[J]. PLoS One, 2018, 13 (11): e0207387
doi: 10.1371/journal.pone.0207387
[53]   ZUCCHELLA M , PACCHIARINI L , TACCONI F et al. Different expression of procoagulant activity in human cancer-cells cultured "in vitro" or in cells isolated from human tumor-tissues[J]. Thromb Haemost, 1993, 69 (4): 335- 338
doi: 10.1055/s-0038-1651608
[54]   HAMADA K , KURATSU J , SAITOH Y et al. Expression of tissue factor correlates with grade of malignancy in human glioma[J]. Cancer, 1996, 77 (9): 1877- 1883
doi: 10.1002/(SICI)1097-0142(19960501)77:9<1877::AID-CNCR18>3.0.CO;2-X
[1] LIN Cuicui, CHEN Zhengyun, WANG Chunyan, XI Yongmei. Research progress on biomarkers for endometriosis based on lipidomics[J]. J Zhejiang Univ (Med Sci), 2020, 49(6): 779-784.
[2] LI Mengyao,LIU Pan,KE Yuehai,ZHANG Xue. Research progress on macrophage in radiation induced lung injury[J]. J Zhejiang Univ (Med Sci), 2020, 49(5): 623-628.
[3] HAN Xue,JIANG Guojun,SHI Qiaojuan. Effects of antihyperglycemics on endothelial progenitor cells[J]. J Zhejiang Univ (Med Sci), 2020, 49(5): 629-636.
[4] DUAN Runping,XU Yesheng,ZHENG Libin,YAO Yufeng. Research progress on etiologic diagnosis of ocular viral diseases[J]. J Zhejiang Univ (Med Sci), 2020, 49(5): 644-650.
[5] WU Wei,XU Jian. Research progress on the role of pentraxin 3 in polycystic ovary syndrome[J]. J Zhejiang Univ (Med Sci), 2020, 49(5): 637-643.
[6] XU Qinglin,LOU Guodong,WANG Tiantian,ZHANG Lisan. Advances in treatment of narcolepsy[J]. J Zhejiang Univ (Med Sci), 2020, 49(4): 419-424.
[7] JIANG Peiran,WANG Zhiping. Progress on axon regeneration in model organisms[J]. J Zhejiang Univ (Med Sci), 2020, 49(4): 500-507.
[8] CHEN Junyi,YANG Xiang,FANG Xuexian,WANG Fudi,MIN Junxia. The role of ferroptosis in chronic diseases[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 44-57.
[9] ZHAO Weixia,ZOU Wei. Intrinsic and extrinsic mechanisms regulating neuronal dendrite morphogenesis[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 90-99.
[10] WANG Yi,LU Yunbi. Poly adenosine diphosphate-ribosylation and neurodegenerative diseases[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 100-106.
[11] YU Qing, XIONG Xiufang, SUN Yi. Targeting Cullin-RING E3 ligases for anti-cancer therapy: efforts on drug discovery[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 1-19.
[12] DUAN Lingyan,YIN Xiangju,MENG Hong'en,FANG Xuexian,MIN Junxia,WANG Fudi. Progress on epigenetic regulation of iron homeostasis[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 58-70.
[13] LI Ai,ZHANG Tianyuan,GAO Jianqing. Progress on utilizing mesenchymal stem cells as cellular delivery system for targeting delivery of as drug/gene for anti-tumor therapy[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 20-34.
[14] HUANG Yaoping,YANG Feng,ZHOU Tianhua,XIE Shanshan. Emerging roles of Hippo signaling pathway in gastrointestinal cancers and its molecular mechanisms[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 35-43.
[15] ZHONG Wen,LOU Yan,QIU Chenyang,LI Donglin,ZHANG Hongkun. Antithrombotic therapy after iliac vein stenting[J]. J Zhejiang Univ (Med Sci), 2020, 49(1): 131-136.